Your organoid or 3D model captures tumor architecture, but are you seeing the full picture? The signaling circuits between cancer cells, stroma, and immune compartments often go undetected in standard culture systems.
What You’ll Learn
See how advanced 3D microtumor platforms and ML-driven screening expose TME-dependent vulnerabilities that conventional approaches miss and how antibody-based tools can intercept the intercellular signals that drive progression.
Key Takeaways
- How a 3D microtumor platform uncovered a p38-dependent tumor–CAF–ECM circuit missed by standard screening
- A noncanonical DDR1/2–p38–GLI1 axis in CAFs as a new antibody-amenable therapeutic target
- Combining kinase inhibition with anti-PD-L1 to boost CD8⁺ T cell infiltration and antitumor response
- Selecting research-grade antibodies to advance 3D tumor model and organoid research
Who Should Attend
Designed for cancer biologists and translational researchers using organoids, 3D tumor models, or antibody-based approaches to study TME signaling.
Our Speakers
Dr. Nao Nishida-Aoki, Global Center for Science and Engineering, Waseda University, Japan
Details
Starts: June 17, 2026 1:00 pm ET
Cost: This event is free for ASCB members and nonmembers to attend.